Deda L, et al. - An inquiry was set up with regard to the vitamin D (VitD) treatment on endothelial function (EF) and markers of renal inflammation, in deficient adolescents with type 1 diabetes. The results shed light on the connection between VitD treatment with an improvement in EF and reduced expression of urinary inflammatory markers in the study cohort. This finding pointed towards an additional benefit of VitD supplementation on early markers of microvascular complications.

Methods

• Herein, adolescents with T1D with suboptimal levels of VitD (<37.5 nmol/L) were treated for 12 to 24 weeks with a VitD analog (VitD3) at doses of 1000 or 2000 IU daily.
• The primary end-point included an analysis of the change in reactive hyperemia index (lnRHI), a measure of EF.
• Secondary end-points comprised of changes in blood pressure, lipid profile, HbA1c and albumin creatinine ratio (ACR).
• In addition, the urinary cytokine/chemokine inflammatory profile was examined amongst a subset of subjects, posttreatment.

Results

• Screening was conducted of 271 individuals for VitD status and 31 VitD deficient subjects with a mean age of 15.77 plusmn; 1.4 years were enrolled and completed the study.
• Mean 25-OH-VitD levels reported a substantial rise (33.0 plusmn; 12.8 vs 67.0 plusmn; 23.2 nmol/L, P < .01) with a notable improvement in EF following VitD supplementation (lnRHI 0.58 plusmn; 0.20 vs 0.68 plusmn; 0.21, P=.03).
• VitD supplementation did not exert any marked effect on the systolic blood pressure/diastolic blood pressure (SBP/DBP), lipids, HbA1c and ACR and there were no adverse effects.
• Several urinary inflammatory cytokines/chemokines: MCP-3 (P < .01), epidermal growth factor (EGF) (P < .01) tumor necrosis factor β (TNFβ) (P=.01), interleukin-10 (IL-10) (P=.01), illustrated a prominent decrease post-VitD-treatment.